IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in IN8BIO, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −1 vs. Q2 2023
- Shares held
- 2.48M
- +147.6K (+6.3%) vs. Q2 2023
- Total value
- $2.58M
- −$1.01M (−28.2%) vs. Q2 2023
- New holders
- 3
- 8 more added
- Sold out
- 4
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 115 | $0 | 0.00% | −148−56.3% | Reduced |
| JPMorgan Chase & Co | 18 | $19 | 0.00% | +18 | New |
| UBS Group AG | 4,968 | $5.17K | 0.00% | +4,968 | New |
| HighTower Advisors, LLC | 10,000 | $10.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 10,219 | $10.6K | 0.00% | +52+0.5% | Added |
| Tower Research Capital LLC (TRC) | 11,734 | $12.2K | 0.00% | +4,960+73.2% | Added |
| Charles Schwab Investment Management Inc | 13,105 | $13.6K | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 14,500 | $15.1K | 0.00% | −1,250−7.9% | Reduced |
| BlackRock Inc. | 29,712 | $30.9K | 0.00% | −15,379−34.1% | Reduced |
| Overbrook Management Corp | 33,756 | $35.1K | 0.01% | 00.0% | Unchanged |
| Texas Capital Bank Wealth Management Services Inc | 42,445 | $44.1K | 0.01% | +42,445 | New |
| Northern Trust Corp | 43,258 | $45.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 59,246 | $61.6K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 78,302 | $81.4K | 0.00% | +29,302+59.8% | Added |
| Rock Creek Group, LP | 151,314 | $157.4K | 0.02% | +75,000+98.3% | Added |
| Stonegate Investment Group, LLC | 180,000 | $187.2K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 188,849 | $196.5K | 0.00% | +12,288+7.0% | Added |
| Sigma Planning Corp | 285,050 | $296.5K | 0.01% | +5,650+2.0% | Added |
| Vanguard Group Inc | 338,728 | $352.3K | 0.00% | +51,161+17.8% | Added |
| Ensign Peak Advisors, Inc | 470,028 | $488.8K | 0.00% | 00.0% | Unchanged |
| Voss Capital, LLC | 511,584 | $532.0K | 0.07% | +53,708+11.7% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −57,722−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −21,700−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −18,189−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −17,583−100.0% | Sold out |